An overview of the design, process, results and recommendations of the recent sero conversion study by the National Centre in HIV Epidemiology and Clinical Research, the Australian Research Centre in Sex, Health and Society, and the National Centre in HIV Social Research.
This presentation was given at the AFAO HIV Educators Conference in May 2008.
Sex, Drugs & Scotland's Health- Experience of aging with HIV in residential c...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Eseoghene Johnson.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
Sex, Drugs & Scotland's Health- Healthcare use among people living with HIV i...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Alastair Hudson.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
Sex, Drugs & Scotland's Health-HPV Vaccine Uptake among eligible GBMSM in the...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Dr Jamie Frankis.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
Sex, Drugs & Scotland's Health- Drug use among people living with HIV in Scot...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Irina Lut.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
An overview of knowledge and use of PrEP among gay men in Australia.
This presentation was given by Dean Murphy, AFAO HIV Education Officer, at the AFAO National HIV Forum, 17 October 2014.
Monitoring and evaluation proposal for National Gay Men’s Syphilis Action Plan. Presentation given by Rebecca Guy and Michelle McPherson at the AFAO National Syphilis Forum, 23 October 2009.
HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophy...Илья Антипин
Holtz TH и др. «HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand» 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, 2015. MOAC0306LB.
An overview of the design, process, results and recommendations of the recent sero conversion study by the National Centre in HIV Epidemiology and Clinical Research, the Australian Research Centre in Sex, Health and Society, and the National Centre in HIV Social Research.
This presentation was given at the AFAO HIV Educators Conference in May 2008.
Sex, Drugs & Scotland's Health- Experience of aging with HIV in residential c...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Eseoghene Johnson.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
Sex, Drugs & Scotland's Health- Healthcare use among people living with HIV i...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Alastair Hudson.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
Sex, Drugs & Scotland's Health-HPV Vaccine Uptake among eligible GBMSM in the...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Dr Jamie Frankis.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
Sex, Drugs & Scotland's Health- Drug use among people living with HIV in Scot...HIVScotland
Delivered at Sex, Drugs & Scotland's Health Virtual Conference, this presentation was delivered by Irina Lut.
More information about the virtual event is available here: http://ow.ly/YntW50GWhJ0
An overview of knowledge and use of PrEP among gay men in Australia.
This presentation was given by Dean Murphy, AFAO HIV Education Officer, at the AFAO National HIV Forum, 17 October 2014.
Monitoring and evaluation proposal for National Gay Men’s Syphilis Action Plan. Presentation given by Rebecca Guy and Michelle McPherson at the AFAO National Syphilis Forum, 23 October 2009.
HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophy...Илья Антипин
Holtz TH и др. «HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand» 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, 2015. MOAC0306LB.
Speakers discuss PrEP eligibility, management, and other topics covered in training modules one and two. During this webinar, expert speakers will review key highlights from the first two modules, share Nigeria specific guidance, and respond to questions from participants.
Part 2: https://www.slideshare.net/jsi/prep-elearning-discussion-2
This workshop will cover best practices for HIV prevention in adolescents with a focus on the implementation of Pre-Exposure Prophylaxis (PrEP) and Post Exposure Prophylaxis (PEP) in SBHCs. Join this workshop to hear an overview of the HIV epidemic among adolescents in California, best practices for determining eligibility for PrEP and PEP, instructions for labs and prescriptions, and suggestions for case management and training of all SBHC staff.
David Wohl, MD, prepared useful Practice Aids pertaining to HIV pre-exposure prophylaxis for this CME/CE activity titled "Breaking Down the Barriers to PrEP: The Patient Journey From Misconceptions to Effective HIV Prevention." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2JovTyb. CME/CE credit will be available until April 19, 2019.
Polypharmacy - What next? (Planning for Wessex) Workshop - Clare Howard's pre...Health Innovation Wessex
Polypharmacy - What next? (planning for Wessex) Conference 30th March 2017
'Polypharmacy Prescribing Comparators' Opening Presentation by Clare Howard, Clinical Lead
This presentation offers stats, trends, and factors associated with higher HIV-infection risk and how clinicians can attend to it.This was my presentation for Bayless Bahavioral Health- Didactic training on 12.10.13, it explores the HIV problem in the US and AZ and
Jill Blumenthal MD of UC San Diego presents "Free to Be You and Me: Providing Culturally-Sensitive Patient Care to Transgender Individuals" at AIDS Clinical Rounds
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Karen Champenois, Maison Blanche Hospital, Paris
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Join us as we discuss best practices for integrating HIV prevention (e.g. HIV testing, PrEP and linkage to care) into primary care within the context of enhancing clinical workforce development.
Panelists:
• Marwan Haddad, MD, MPH, AAHIVS, Medical Director, Center for Key Populations, Community Health Center, Inc.
• Jeannie McIntosh, APRN, FNP-C, AAHIVS, Family Nurse Practitioner, Center for Key Populations, Community Health Center, Inc.
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...hivlifeinfo
Contemporary Management of HIV. Antiretroviral Therapy As Prevention.2016
In this downloadable slideset, Kenneth Mayer, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for pre- and post-exposure prophylaxis in patients at risk for HIV infection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.13 MB
Where's the hope? Dialogues for Solidarity - Session 4ReShape
This session explored current work experiences in HIV care from a specialist point of view and looked at how current conditions impacted related care providers. Reflecting on the changing nature of HIV care and the changing needs of people living with HIV, the session examined the policy implications of a fragmented system and the patients' perspective on HIV care.
The Care Providers session was expected to lay the groundwork for a future session on the failing Health Economy as a leading issue.
Where's the hope? Dialogues for Solidarity - Session 1ReShape
Session 1: GIPA Principles for the 21st Century with guest, Sean Strub, Sero Project, USA
Where’s the Hope?, a year-long series of dialogues for solidarity, is coordinated by ReShape, an independent London-based think tank formed to respond to the ongoing crisis in sexual health.
Working together, activists and organisers will share their experiences and explore new op- portunities to address explore chronic obstacles to successful organising in HIV, HCV and re- lated sexual and mental health concerns. Emerging advocates and organisers are especially welcome.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
3. • Estimated 3,000 ChemSex presentations per month
• 100 per month willing to access behaviour change support
• Multiple partners per ChemSex episode
• Multiple PEP presentations
• Poor condom use common
• Good ARV adherence amongst HIV+ve cohort
• Little experience of sober sex
• Potential clusters of new HIV infections within ChemSex “scenes”
• Very high PrEP interest
• Increasing injecting use, poor safer injecting awareness – HCV risks
• Multiple HCV re-infections, including amongst HIV-ve non-injecters
@davidastuart
Results
Ref; Stuart, David, and Johannes Weymann. "ChemSex and Care-panning: One Year in Practice."
HIV Nursing Journal 15, no. 2 (2015): 24, 25, 26, 27, 28
4. Identifying high risk
• Drugs Used; Crystal methamphetamine, Mephedrone, GHB/GBL being highest risk drugs
• Frequency of drug-using episodes and frequency of sober sex encounters
• Number of partners per drug-using episode
• Prevalence of condomless sex per drug-using episode (sorted by HIV-ve, HIV+ve, those
on treatment, those undetectable)
• Route of drug administration (snorted, injected, swallowed, booty-bumped/intra-anal)
• Likelihood of traumatic sex during drug-using episode
• Alerts for:
o Seroconversion symptoms
o HIV+ve not on treatment
o Poor antiretroviral adherence (where likely to impact viral suppression)
o High number of PEP presentations/courses prescribed
o Infrequent HIV screening/GUM attendance
o Frequent GUM infections
o Frequent overdoses linked to possible drug interactions
o HCV infection
o Sharing of drug use equipment
o Fisting
5. •“Do you use Party Drugs for sex?”
•(and if so…) “Tina, Mephedrone or G”
•“How long do you stay awake for?”
•“Have you had any bad experiences?” (eg; paranoia)
•“Do you sometimes regret the choices you make when high?”
•When did you last have sober sex?
•“What’s your non-sexual/non-clubbing social life like?”
•“Are you slamming (injecting) ?”
•“Do you want to talk to someone about being safer with
drugs?”
Questions to ask
@davidastuart
@davidastuart
9. WWW.CHEMSEXSUPPORT.COM
(FROM 56 DEAN STREET)
@davidastuart
For chem users
How to access support
Tips for safer use/drug info/sexual health info
Behaviour change video library (craving
management, reduction tips, sober sex advice,
safer play information)
List of London recreational/social alternatives to
bars, clubs, saunas, chems
DS16
10. WWW.CHEMSEXSUPPORT.COM
(FROM 56 DEAN STREET)
@davidastuart
For professionals
• A working definition, ChemSex
• Referral information
• Video tutorials/conducting
ChemSex interventions
• Resources/tools for working with
ChemSexers
• Papers on adapting services
to be ChemSex efficient
• ChemSex research
• Drug–drug interactions
DS17